logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Hôpital Haut-Lévêque Chu De Bordeaux

+33556795679

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Hôpital Haut-Lévêque is a major public healthcare facility located at Avenue de Magellan in Pessac (33600), France, and operates as a core component of the South Hospital Group within the Bordeaux University Hospital (CHU de Bordeaux) network. As the newest of the city's three main university hospital sites, it spans an expansive campus alongside its sister facility, Hôpital Xavier-Arnozan. The hospital is highly regarded as a regional center of excellence, specializing in complex medical and surgical fields such as advanced cardiology, thoracic and respiratory pathologies, digestive system diseases, and oncology. Functioning simultaneously as a high-capacity treatment facility and an active clinical research site, Hôpital Haut-Lévêque houses the specialized Magellan Medico-Chirurgical Center and features extensive outpatient, emergency, and specialized surgical services.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. University hospital

Business Subcategory

Source: Human-provided. University hospital
Source: Trial-derived.
157Total Trials
Source: Trial-derived.
31Recruiting Trials
Source: Trial-derived.
85Active Trials
Source: Trial-derived.
56Completed Trials
Source: Trial-derived.
227Unique Conditions
Source: Trial-derived.
145Unique Sponsors

Conditions

Source: Trial-derived. Multiple Myeloma (7)Source: Trial-derived. Bradycardia (4)Source: Trial-derived. Crohn's Disease (4)Source: Trial-derived. Neoplasms (4)Source: Trial-derived. Acute Myeloid Leukemia (3)Source: Trial-derived. Atrial Fibrillation (3)Source: Trial-derived. Chronic Lymphocytic Leukemia (3)Source: Trial-derived. Diffuse Large B-cell Lymphoma (3)

Sponsors

Source: Trial-derived. University Hospital, Bordeaux (18)Source: Trial-derived. AbbVie (7)Source: Trial-derived. Hoffmann-La Roche (7)Source: Trial-derived. Hospices Civils de Lyon (7)Source: Trial-derived. Janssen Research & Development, LLC (7)Source: Trial-derived. Assistance Publique - Hôpitaux de Paris (6)Source: Trial-derived. Ministry of Health, France (4)Source: Trial-derived. Rennes University Hospital (4)

Facilities & Operations

Facilities and operational capabilities inferred from trial participation

Source: AI-inferred. Overnight or inpatient research stays supported

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture
Source: AI-inferred. Telehealth study visits
Source: AI-inferred. Electronic source (eSource) system

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. CT Scan
Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. PET-CT
Source: AI-inferred. Cardiac device interrogation and programming
Source: AI-inferred. MRI
Source: AI-inferred. Vibration-controlled transient elastography (FibroScan)
Source: AI-inferred. 12-lead ECG
Source: AI-inferred. Ambulatory ECG / Holter monitoring

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. PCR / molecular
Source: AI-inferred. Pharmacokinetic bioanalysis
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Sequencing / genomics
Source: AI-inferred. ELISA / immunoassay

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Endoscopy / colonoscopy
Source: AI-inferred. Apheresis
Source: AI-inferred. Cardiac catheterisation or electrophysiology procedures
Source: AI-inferred. Liver biopsy
Source: AI-inferred. Radiopharmaceutical handling and administration
Source: AI-inferred. Blood transfusion service
Source: AI-inferred. Cardiac implantable electronic device implantation

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Minimal residual disease (MRD) testing
Source: AI-inferred. Allogeneic haematopoietic stem cell transplantation
Source: AI-inferred. Bone marrow cytology
Source: AI-inferred. Chromosome 17p deletion testing
Source: AI-inferred. Coronary CT angiography
Source: AI-inferred. Cytogenetic karyotyping
Source: AI-inferred. Electronic clinical outcome assessment (eCOA/ePRO) platform
Source: AI-inferred. Fundus examination